Effect of Imatinib Mesylate Combined with Granulocyte Colony-Stimulating Factor on Leukaemic Blast Cells Derived from Advanced-Stage Chronic Myelogenous Leukaemia Patients

2006 ◽  
Vol 116 (1) ◽  
pp. 8-18 ◽  
Author(s):  
Shuichi Ota ◽  
Manabu Musashi ◽  
Keiichi Kondo ◽  
Nobuyasu Toyoshima ◽  
Tomomi Toubai ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Chronic Myelogenous Leukaemia ◽  
Myelogenous Leukaemia ◽  
Advanced Stage ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Blast Cells ◽  
Stimulating Factor ◽  
Leukaemic Blast

Granulocyte Colony Stimulating Factor Increases Drug Resistance of Leukaemic Blast Cells to Daunorubicin

2008 ◽  
Vol 14 (3) ◽  
pp. 285-292 ◽  
Author(s):  
László Márkász ◽  
György Hajas ◽  
Andrea Kiss ◽  
Beáta Lontay ◽  
Éva Rajnavölgyi ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Blast Cells ◽  
Stimulating Factor ◽  
Leukaemic Blast

Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study.

1998 ◽  
Vol 16 (2) ◽  
pp. 522-526 ◽  
Author(s):  
J Laver ◽  
M Amylon ◽  
S Desai ◽  
M Link ◽  
M Schwenn ◽  
...  
Keyword(s):  
T Cell ◽  
Lymphoblastic Lymphoma ◽  
High Dose ◽  
Induction Phase ◽  
Advanced Stage ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Cell Leukemia ◽  
Continuation Therapy ◽  
Stimulating Factor

PURPOSE Contemporary chemotherapy has significantly improved the event-free survival (EFS) among patients with T-cell disease. However, myelosuppression has been a significant adverse effect of this approach. In this study, we assessed the impact of r-metHu granulocyte colony-stimulating factor (G-CSF) on the period of neutropenia, number of days of hospitalization, and delays in subsequent administration of chemotherapy in a cohort of patients with T-cell leukemia (T-ALL) or advanced stage lymphoblastic lymphoma (ASLL). PATIENTS AND METHODS This open-label, randomized trial incorporated r-metHuG-CSF into the induction and two consecutive continuation-therapy cycles of our intensive program for T-cell malignancies. In the induction phase, r-metHuG-CSF was given after two different combinations of chemotherapy, one of which included vincristine, prednisone, cyclophosphamide, and adriamycin and the other a continuous infusion of high-dose ara-C and L-asparaginase. In the two continuation-therapy cycles, r-metHuG-CSF was given following the combination of vincristine, adriamycin, prednisone, and 6-mercaptopurine (MP) and after continuous infusion of high-dose cytarabine (ara-C). RESULTS Fifty-six patients with T-ALL and 33 with ASLL were enrolled onto study from April 1994 to December 1995. Our data show no significant difference in number of days of absolute neutrophil count (ANC) less than 500/microL, hospitalizations, or delays in therapy in the induction phase. However, in the continuation-therapy phase the number of days of ANC less than 500/microL was significantly shorter (P = .017) on the G-CSF-arm without significantly affecting the number of days of hospitalizations or delays in therapy. CONCLUSION r-metHuG-CSF did not significantly affect the period of neutropenia, hospitalization, or delays in therapy in the induction phase, whereas in the two cycles of continuation therapy, it significantly shortened the period of neutropenia.

scholarly journals Granulocyte colony-stimulating factor receptors in human acute myelocytic leukemia

Blood ◽  
1989 ◽  
Vol 74 (8) ◽  
pp. 2668-2673 ◽  
Author(s):  
LM Budel ◽  
IP Touw ◽  
R Delwel ◽  
B Lowenberg
Keyword(s):  
Specific Binding ◽  
Acute Myelocytic Leukemia ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Potent Inducer ◽  
Myelocytic Leukemia ◽  
Human Acute Myeloid Leukemia ◽  
Blast Cells ◽  
Stimulating Factor

Abstract The binding of granulocyte colony-stimulating factor (G-CSF) to normal and human acute myeloid leukemia (AML) cells was investigated with radiolabeled recombinant human G-CSF (rhG-CSF). In all 14 cases of primary AML specific receptors for G-CSF were demonstrated on purified blast cells. The average numbers of G-CSF receptors ranged from very low to 428 receptors per cell (mean). Normal granulocytes showed G-CSF binding sites on their surface at higher densities (703 to 1,296 sites per cell). G-CSF receptors appeared to be of a single affinity type with a dissociation constant (kd) ranging between 214 and 378 pmol/L for AML blasts and 405 to 648 pmol/L for granulocytes. In 12 of 14 cases, including those with relatively low specific binding, G-CSF was a potent inducer of DNA synthesis of blasts in vitro; therefore, apparently relatively few receptors are required to permit activation of AML cell growth. However, in two cases cell cycling was not activated in response to G-CSF despite G-CSF receptor availability. The results show that G-CSF receptors of high affinity are frequently expressed on the blasts of human AML, but their presence may not be a strict indicator of the proliferative responsiveness of the cells to G- CSF.

Sign in / Sign up

Export Citation Format

Share Document